中文摘要：

目的：探讨多巴胺能药物及其它因素与早期帕金森病患者睡眠障碍之间的关系。方法：选择84名早期帕金森病患者作为病例组,87名健康人作为对照组。采用帕金森病睡眠量表（PDSS）评价患者的睡眠状况。采用非条件Logistic回归分析早期帕金森病患者睡眠障碍的影响因素。结果：早期帕金森病组PDSS总评分显著低于对照组（P=0.000）；HAMD评分则显著高于对照组（P=0.000）。早期帕金森病患者睡眠障碍的主要类型为失眠。使用多巴胺能药物（OR=5.50,95%CI：1.96-15.81）是早期帕金森病患者发生睡眠障碍的危险因素；而较低的HAMD评分（OR=0.35,95%CI：0.13-0.93）则显著降低其睡眠障碍风险。结论：早期帕金森病患者存在睡眠障碍,多巴胺能药物和抑郁可能促进和加重其睡眠障碍。

英文摘要：

Objective： To evaluate the relationship between dopaminergic agents and sleep disorders of Parkinson disease（PD）patients at early stage. Methods： Eighty-four consecutive PD patients at early stage（Hoehn-Yahr grade Ⅰ- Ⅱ） and age-matched 87 healthy controls were enrolled in this study. Parkinson disease sleep scale（PDSS） was used to evaluate sleep status. Non-conditional Logistic regression models were used to calculate odds ratios and its corresponding 95% confidence interval（95%CI）. Results： The PDSS score of PD group was significantly lower than that of control group（P=0.000）, but the score of Hamilton depression rating scale（HAMD） of PD group was significantly higher than that of control group（P=0.000）. Agrypnia was found the main type of sleep disorder for PD patients at early stage. Dopaminergic agents（OR=5.50, 95%CI： 1.96-15.81） could increase risk of sleep disturbance, and lower score of HAMD（OR=0.35, 95%CI： 0.13-0.93） could decrease risk of sleep disorders among PD patients. Conclusion： Different types of sleep disorder could be found in PD patients at early stage. Dopaminergic agents and depression may make the situation of sleep disorders worse for PD patients at early stage. Intervention and treatment measures should be introduced to prevent development of sleep disorders among PD patients at early stage.